WeVote
Log In

Bill

Bill

H 1125

An Act relative to non-medical switching

194th Legislature (2025-2026)

Restricts health insurers from forcing medication switches without medical justification, requiring appeals processes to protect patients on stable treatments.

Accompanied a new draft, see H4491
0
WeVote Research Nonpartisan
Bill Summary · H 1125

Legislative bill overview

H 1125 addresses "non-medical switching," which occurs when insurance companies force patients to switch from their current prescription medications to different drugs—typically cheaper alternatives—without medical justification. The bill aims to protect patients by restricting insurers' ability to make these switches and establishing requirements for prior authorization and appeals processes.

Why is this important

Non-medical switching can disrupt treatment for patients whose current medications are working well, potentially causing health complications, increased hospitalizations, or treatment failures. This practice disproportionately affects individuals with chronic conditions (like diabetes, depression, or heart disease) who have found stable medication regimens. The bill addresses a real tension between insurance cost-control measures and patient health outcomes.

Potential points of contention

  • Industry opposition: Insurance companies and pharmacy benefit managers argue switching to generic or lower-cost alternatives reduces premiums for all consumers; restricting this practice may increase healthcare costs
  • Definition and scope: What qualifies as "non-medical" switching versus medically appropriate generic substitution requires careful definitional lines that could be contentious
  • Implementation complexity: Determining when a switch is truly non-medical versus cost-justified requires medical review processes that add administrative burden and potential delays in coverage decisions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.